Beth Adamson

Beth Adamson

Auto-generated profile, based on publicly available information

Beth Adamson

Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Resistance to androgen receptor (AR)–targeted therapies represents a major challenge in prostate cancer. A key mechanism of treatment resistance in patients who progress to castration-resistant prostate cancer (CRPC) is the generation of alternatively spliced AR variants (AR-V). Unlike full-length AR isoforms, AR-Vs are constitutively active and refractory to current receptor-targeting agents and hence drive tumor progression. Identifying regulators of AR-V synthesis may therefore provide new therapeutic opportunities in combination with conventional AR-targeting agents. Our understanding of AR transcript splicing, and the factors that control the synthesis of AR-Vs, remains limited. Although candidate-based approaches have identified a small number of AR-V splicing regulators, an unbiased analysis of splicing factors important for AR-V generation is required to fill an important knowledge gap and furnish the field with novel and tractable targets for prostate cancer treatment. To that end, we conducted a bespoke CRISPR screen to profile splicing factor requirements for AR-V synthesis. MFAP1 and CWC22 were shown to be required for the generation of AR-V mRNA transcripts, and their depletion resulted in reduced AR-V protein abundance and cell proliferation in several CRPC models. Global transcriptomic analysis of MFAP1-depleted cells revealed both AR-dependent and -independent transcriptional impacts, including genes associated with DNA damage response. As such, MFAP1 downregulation sensitized prostate cancer cells to ionizing radiation, suggesting that therapeutically targeting AR-V splicing could provide novel cellular vulnerabilities which can be exploited in CRPC. Implications: We have utilized a CRISPR screening approach to identify key regulators of pathogenic AR splicing in prostate cancer.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Supplementary Table S10 from Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S1. Development of the inducible Cas9 CWR22Rv1-AR-EK derivative cell line (CWR22Rv1-AR-EK-iCas9)

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S11. RNA sequencing samples were confirmed to have depletion of MFAP1, total AR and AR-V7 by western blot and RT-qPCR.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S5. Initial assessment of knockout hits from CRISPR screen highlights MFAP1 and CWC22 as regulators of AR-V abundance.

19 June 2026
Verified
Other
Open access
LWLaura Walker
Laura Walker
RDRuaridh Duncan
Ruaridh Duncan
BABeth Adamson
Beth Adamson
HKHannah Kendall
Hannah Kendall
NBNicholas Brittain
Nicholas Brittain
LGLuke Gaughan
Luke Gaughan
Figure S2. Validating inducible Cas9 activity in the CWR22Rv1-AR-EK-iCas9 cell line.